72 related articles for article (PubMed ID: 8865868)
1. Plasminogen activator inhibitor-1 and peritoneal transport in peritoneal dialysis patients.
Wadhwa NK; Lin JJ; Parton L; Bereket G; Cabralda T; Suh H
Adv Perit Dial; 1996; 12():33-8. PubMed ID: 8865868
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients.
Lin JJ; Parton L; Bereket G; Wadhwa NK
Clin Nephrol; 1995 Nov; 44(5):310-5. PubMed ID: 8605711
[TBL] [Abstract][Full Text] [Related]
3. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
[TBL] [Abstract][Full Text] [Related]
4. Correlations between plasminogen activator inhibitor-1 and peritoneal transport in pediatric CCPD patients.
Lin JJ; Singhal K; Parton L; Cascio C; Patlak CS; Stewart CL
Perit Dial Int; 1995; 15(6):246-51. PubMed ID: 7578502
[TBL] [Abstract][Full Text] [Related]
5. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
Arikan H; Koc M; Sari H; Tuglular S; Ozener C; Akoglu E
Ren Fail; 2007; 29(6):713-9. PubMed ID: 17763167
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of peritoneal transport properties at onset of peritoneal dialysis and longitudinal follow-up.
Clerbaux G; Francart J; Wallemacq P; Robert A; Goffin E
Nephrol Dial Transplant; 2006 Apr; 21(4):1032-9. PubMed ID: 16364990
[TBL] [Abstract][Full Text] [Related]
7. Differences in peritoneal equilibration test results in patients aged above or below 60 years.
Grzegorzewska AE; Leander M; Mariak I
Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583
[TBL] [Abstract][Full Text] [Related]
8. Drain volume required for a target peritoneal clearance: formulae based on peritoneal transport type and body size.
Tzamaloukas AH; Malhotra D; Murata GH
ASAIO J; 1998; 44(6):828-34. PubMed ID: 9831093
[TBL] [Abstract][Full Text] [Related]
9. Outcome for continuous ambulatory peritoneal dialysis patients is not predicted by peritoneal permeability characteristics.
Passadakis PS; Thodis ED; Panagoutsos SA; Selisiou CA; Pitta EM; Vargemezis VA
Adv Perit Dial; 2000; 16():2-6. PubMed ID: 11045251
[TBL] [Abstract][Full Text] [Related]
10. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Opatrný K; Opatrná S; Vít L; Opatrný K
Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033
[TBL] [Abstract][Full Text] [Related]
11. Solutes transport characteristics in peritoneal dialysis: variations in glucose and insulin serum levels.
da Silva DR; Figueiredo AE; Antonello IC; Poli de Figueiredo CE; d'Avila DO
Ren Fail; 2008; 30(2):175-9. PubMed ID: 18300117
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis.
Twardowski ZJ; Moore HL; Prowant BF; Satalowich R
Adv Perit Dial; 2009; 25():155-64. PubMed ID: 19886338
[TBL] [Abstract][Full Text] [Related]
13. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
[TBL] [Abstract][Full Text] [Related]
14. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.
Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C
Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604
[TBL] [Abstract][Full Text] [Related]
15. [Peritoneal equilibrium test with hypertonic exchange: practical application in a peritoneal dialysis program].
Ortiz A; Marrón B; Berlanga JR; Reyero A; Gazapo R
Nefrologia; 2001; 21(4):362-9. PubMed ID: 11816512
[TBL] [Abstract][Full Text] [Related]
16. [Mathematical analysis of the possibilities of automated peritoneal dialysis optimization].
Baczyński D; Antosiewicz S; Waniewski J; Marciniak M; Wańkowicz Z
Pol Merkur Lekarski; 2002 Nov; 13(77):384-8. PubMed ID: 12621754
[TBL] [Abstract][Full Text] [Related]
17. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F
Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295
[TBL] [Abstract][Full Text] [Related]
18. Residual renal function, peritoneal transport characteristics and dialysis adequacy in peritoneal dialysis.
Heimbürger O
Kidney Int Suppl; 1996 Nov; 56():S47-55. PubMed ID: 8914054
[TBL] [Abstract][Full Text] [Related]
19. Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?
Barreto DL; Coester AM; Struijk DG; Krediet RT
Perit Dial Int; 2013; 33(5):529-37. PubMed ID: 23994841
[TBL] [Abstract][Full Text] [Related]
20. Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis.
Malik AR; Little MA; Henriksson M; Tam FW; Brown EA
J Nephrol; 2007; 20(3):340-9. PubMed ID: 17557268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
